ADCs & Engineered Antibodies
The ADC renaissance is here to stay with increased innovation, investments, and collaborations leading to more approvals of safe and effective ADCs on the market.
With positive clinical readouts continuing, capitalize on novel conjugates, payloads, and targets, and optimize clinical trial and manufacturing best practice to develop the next generation of ADCs for oncology patients in need.
Maximizing the Therapeutic Window of ADCs & Engineered Antibodies
The ADC team ploughs its collective energy into sourcing the insights you need. We bring solutions to the most challenging problems facing ADC development; source the leading experts who define best practice; and distil this into accessible formats of information exchange.
From globally leading conferences, the Beacon drug development database, to bespoke networks and market reports, the ADC team at Hanson Wade can offer you the insights you need to accelerate your ADC programs through the clinic.
We endeavor to be your one stop shop for actionable ADC insight. Whether it’s looking at the next generation of drug conjugates, maximizing the clinical potential of ADCs or enhancing the efficiency of complex ADC manufacturing, we cover it for you.
Featured ADCs & Engineered Antibodies Products
Beacon
Conferences
Intelligence
ADCs & Engineered Antibodies Products by Type
Make Faster, Better Drug Development Decisions
Premium Insight and Meaningful Connections for Biopharma
Expert-driven, Life Science Market Intelligence Solutions
CONTACT US
Get in touch
We speak to hundreds of biopharmaceutical experts from industry and academia every day. We would love for you to be one of them. Contact us to discover how our events can accelerate your drug development.
Standard Form - ADCs & Engineered Antibodies
"*" indicates required fields